ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

10:30AM-12:30PM: Abstract Number: 1156

Incidence and Prevalence of Interstitial Pneumonia with Autoimmune Features in a Population-Based Cohort

(1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1464

Incidence of Major Adverse Cardiovascular Events (MACE) in Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis Patients With and Without Cardiovascular Risk Factors Treated With Secukinumab: Five-Year Safety Data from the Real-World SERENA Study

(1434–1466) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1072

Inclusion of Older Adults in Pharmacologic Randomized Controlled Clinical Trials of Autoimmune Rheumatic Diseases: A Systematic Review

(1055–1087) Healthcare Disparities in Rheumatology Posters

10:30AM-12:30PM: Abstract Number: 1186

Increased Adoption of IL-1 Pathway Inhibition and the Steroid-sparing Paradigm Shift: Temporal Trends in Recurrent Pericarditis Treatment From the RESONANCE Patient Registry

(1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 0963

Increased expression of M2 pro-fibrotic markers in circulating monocytes and cultured monocyte-derived macrophages from systemic sclerosis patients with progressive interstitial lung disease (ILD)

(0955–0977) Systemic Sclerosis & Related Disorders – Basic Science Poster I

10:30AM-12:30PM: Abstract Number: 1118

Increased Risk of Azathioprine-Induced Leukopenia in Patients with Systemic Lupus Erythematosus: A 10-Year Retrospective Cohort Study at a Quaternary Care Hospital in Thailand

(1088–1122) Immunological Complications of Medical Therapy Poster

10:30AM-12:30PM: Abstract Number: 1137

Increased Risk of Cardiovascular Events and Mortality Related to Diffuse Idiopathic Skeletal Hyperostosis (DISH): A Systematic Review and Meta-Analysis

(1123–1146) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 1270

Increasing Participation in the FT819 Cell Therapy Trial Amongst People Living with Lupus: A Focus Group Study

(1248–1271) Patient Outcomes, Preferences, & Attitudes Poster II

10:30AM-12:30PM: Abstract Number: 1260

Increasing Zoster Vaccination Rates in Immunosuppressed Veterans at the North Texas VA Medical Center Rheumatology Clinic

(1248–1271) Patient Outcomes, Preferences, & Attitudes Poster II

10:30AM-12:30PM: Abstract Number: 1198

Induction of stable, GC-free remission in patients with severe, therapy-refractory anti-synthetase syndrome after using the bispecific CD19xCD3 T cell engager blinatumomab

(1191–1220) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1117

Inflammatory Arthritis after Hematopoietic Stem Cell Transplant: A Case Series and Literature Review

(1088–1122) Immunological Complications of Medical Therapy Poster

10:30AM-12:30PM: Abstract Number: 1339

Inflammatory Rheumatic Diseases in IDH-mutated Myeloid Neoplasms: Clinical Spectrum and Response to IDH Inhibitors

(1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1396

Influence of Age on Daily Impairment, Patient Empowerment, Activation and Engagement in Patients with Sjögren’s Disease

(1376–1404) Sjögren’s Disease – Basic & Clinical Science Poster II: Clinical Manifestations and Health Outcomes

10:30AM-12:30PM: Abstract Number: 1528

Influence of Prednisone use over cardiovascular risk in patients with Systemic Lupus Erythematosus

(1517–1552) Systemic Lupus Erythematosus – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1448

Influence of Sex on the Therapeutic Persistence of Guselkumab in Psoriatic Disease: a Retrospective National Cohort Study

(1434–1466) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].